Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORESA Study
2024-512313-41-00Phase 3Suspended
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of Compound Danshen in stable angina (3 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: Change in symptom-limited total exercise duration (TED) at trough drug levels on standard Bruce protocol from baseline to Day 57, Frequency and severity of adverse events and serious adverse events and 1 more. Started Nov 2024; status: suspended.
02
Drugs
Compound Danshen
03
Conditions
stable angina
Beyond the preview
Go deeper on 2024-512313-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512313-41-00.